Trans-Resveratrol
Metabolic Syndrome X
University of GuadalajaraPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Metabolic Syndrome X cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BBB |
Cilnidipine Boryung Pharmaceutical Co., Ltd | Phase 4 | BB |
TAMOXIFEN Veterans Medical Research Foundation | Phase 4 | BB |
EXEMESTANE Veterans Medical Research Foundation | Phase 4 | BB |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Korea University Anam Hospital | Phase 4 | BB |
View all 25 →
Same molecule, other indications
Trans-Resveratrol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →